Sign up to save your podcasts
Or
Share Chronic Lymphocytic Leukemia — An Interview with Dr Catherine C Coombs on Real-World Cases and Current Questions and Controversies Presented at Recent Conferences
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Chronic Lymphocytic Leukemia — An Interview with Dr Catherine C Coombs on Real-World Cases and Current Questions and Controversies Presented at Recent Conferences
Featuring an interview with Dr Catherine C Coombs, including the following topics:
- Case: A woman in her early 80s with dementia and newly diagnosed IGHV-mutated del(13q) chronic lymphocytic leukemia (CLL) receives initial treatment with zanubrutinib (0:00)
- Current and investigational initial therapy approaches for CLL (13:41)
- Case: A man in his late 40s under observation for asymptomatic CLL develops worsening symptoms and initiates treatment with venetoclax/obinutuzumab (28:15)
- Phase III AMPLIFY trial of fixed-duration acalabrutinib combined with venetoclax with or without obinutuzumab as first-line treatment for CLL (36:02)
- Other novel venetoclax combinations for the treatment of CLL (43:36)
- Case: A man in his mid 70s with multiregimen-refractory CLL receives pirtobrutinib (46:51)
- Personal perspectives on the activity and tolerability of pirtobrutinib; sequencing pirtobrutinib and chimeric antigen receptor T-cell therapy for patients with CLL (51:16)
CME information and select publications
View all episodes
By Dr Neil Love
4.6
103103 ratings
Featuring an interview with Dr Catherine C Coombs, including the following topics:
- Case: A woman in her early 80s with dementia and newly diagnosed IGHV-mutated del(13q) chronic lymphocytic leukemia (CLL) receives initial treatment with zanubrutinib (0:00)
- Current and investigational initial therapy approaches for CLL (13:41)
- Case: A man in his late 40s under observation for asymptomatic CLL develops worsening symptoms and initiates treatment with venetoclax/obinutuzumab (28:15)
- Phase III AMPLIFY trial of fixed-duration acalabrutinib combined with venetoclax with or without obinutuzumab as first-line treatment for CLL (36:02)
- Other novel venetoclax combinations for the treatment of CLL (43:36)
- Case: A man in his mid 70s with multiregimen-refractory CLL receives pirtobrutinib (46:51)
- Personal perspectives on the activity and tolerability of pirtobrutinib; sequencing pirtobrutinib and chimeric antigen receptor T-cell therapy for patients with CLL (51:16)
CME information and select publications
More shows like Research To Practice | Oncology Videos
View all
Gastrointestinal Cancer Update
17 Listeners
Lung Cancer Update
32 Listeners
Prostate Cancer Update
16 Listeners
Breast Cancer Update
62 Listeners
PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
10 Listeners
Gynecologic Oncology Update
12 Listeners
Hematologic Oncology Update
73 Listeners
Dermatologic Oncology Update
0 Listeners
Medgeeks Clinical Review Podcast
962 Listeners
PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
13 Listeners
JAMA Clinical Reviews
479 Listeners
ASCO Daily News
55 Listeners
The ONS Podcast
196 Listeners
ASCO Guidelines
44 Listeners
OncLive® On Air
21 Listeners
Plenary Session
745 Listeners
Oncology Today with Dr Neil Love
55 Listeners
Two Onc Docs
165 Listeners
Oncology Brothers: Practice-Changing Cancer Discussions
37 Listeners